Tandem Diabetes Care Earnings Call Signals Strategic Shift

Tandem Diabetes Care ((TNDM)) has held its Q4 earnings call. Read on for the main highlights of the call.

Tandem Diabetes Care’s latest earnings call mixed celebration with realism as executives detailed record revenue, expanding margins and a stronger balance sheet while openly flagging 2026 revenue headwinds from a shift to a pharmacy PayGo model and direct international sales. Management framed these pressures as deliberate, near-term trade-offs to build a higher-margin, more predictable recurring revenue base by 2026.

Record Revenue Milestone and Growth Mix

Tandem crossed the $1.0 billion annual revenue mark in 2025, with worldwide sales rising 12% year over year. U.S. sales climbed 10% to $707 million, while international revenue grew 15% to $308 million, underlining the company’s balanced growth across geographies.

Q4 Acceleration in Sales and Shipments

Fourth quarter results were particularly strong, with worldwide sales reaching a record $290 million, up 15% from a year earlier. U.S. revenue grew 14% to $210 million on more than 27,000 pump shipments, while international sales advanced 17% to $80 million with about 11,000 pumps shipped.

Margin Expansion and Return to Profitability

Profitability metrics improved sharply as full-year gross margin widened by three points to 54% and Q4 gross margin hit a record 58%. Adjusted EBITDA reached 11% of sales in the quarter and operating margin turned positive at 3%, marking a roughly 15-point swing from the prior year.

Strengthened Cash Position and Free Cash Flow

The company exited 2025 with nearly $300 million in cash and investments, providing ample liquidity to fund its strategic transition. Tandem also generated free cash flow in both the third and fourth quarters, ending the year free cash flow positive despite ongoing investments.

Deep Product and Technology Pipeline

Management highlighted a robust pipeline including Control-IQ+ for younger type 1 patients and adults with type 2, integration with FreeStyle Libre 3 Plus, and Android control for the Mobi pump. Near-term catalysts include broader Mobi rollouts, new sensor integrations and regulatory steps toward a Mobi Tubeless patch pump targeted for launch in the second half of 2026.

Commercial Modernization and Direct International Push

Tandem is overhauling its commercial infrastructure, expanding the U.S. sales force and upgrading sales systems while shifting to direct operations in markets such as the U.K., Switzerland and Austria. These initial moves, including distributor separations and new teams, are expected to serve as a blueprint for further direct expansion through 2027.

Pharmacy Strategy and PayGo Adoption

Momentum in the pharmacy channel is building, with U.S. pharmacy sales nearly doubling sequentially in Q4 to $16 million, or 7% of domestic revenue. The company is accelerating a pay-as-you-go model that should improve access and long-term reimbursement economics, with pharmacy expected to reach about 15% of U.S. sales in 2026.

2026 Targets for Revenue, Shipments and Margins

For 2026, management forecast worldwide sales of $1.065 billion to $1.085 billion, a figure that already bakes in an estimated $85 million to $95 million of strategic headwinds. U.S. sales are projected at $730 million to $745 million with pump shipments up 10% to 11%, while gross margin is expected to rise to roughly 56% to 57% for the full year.

Near-Term Revenue Drag from PayGo Transition

The transition to PayGo will weigh on reported revenue as accounting shifts from upfront pump sales to recurring supply purchases. Tandem expects $70 million to $80 million of pricing headwinds in the U.S. and total worldwide revenue pressure of $85 million to $95 million in 2026 as the new model ramps.

Distributor Destocking and Inventory Actions

Distributor destocking and inventory buybacks created about $7 million of drag in 2025, slightly better than earlier expectations. For 2026, the company anticipates roughly $15 million of additional impact tied to the move toward direct international operations, with some of that timing landing in the first quarter.

Short-Term Margin and EBITDA Volatility

Despite the margin uptrend, management warned of volatility as the transition unfolds, guiding to full-year 2026 adjusted EBITDA of 5% to 6%. The first quarter is expected to be soft, with adjusted EBITDA between negative 2% and negative 1% of sales and gross margin near 54% before improving toward 60% by the fourth quarter.

Pharmacy Penetration and Formulary Constraints

Pharmacy penetration remains low for now, with only a small share of the U.S. installed base ordering supplies through this channel at year-end 2025. Limited formulary access means uptake will start from a modest base and scale gradually through 2026, even though contracts cover a majority of lives.

International Transition Costs and Complexity

The move to direct operations overseas is proving complex and multi-year, carrying both costs and temporary revenue disruption. The company recorded about a $4 million impact in Q4 from changes in Switzerland, the U.K. and Austria and expects the broader transition to extend through 2027.

Moderated 2026 Revenue Growth Despite Shipment Gains

Because more revenue will be recognized over time under PayGo rather than upfront, reported 2026 sales growth will likely appear subdued relative to the underlying business momentum. Management urged investors to focus on pump shipment growth as the best indicator of market expansion and future recurring revenue.

Regulatory Timing Risk for Mobi Tubeless

Tandem is planning a regulatory submission for Mobi Tubeless, its first patch pump with extended wear, in the second quarter with an eye toward a launch in the back half of 2026. However, leadership acknowledged approval timing remains an execution risk and has not included potential benefits from this product in its 2026 outlook.

Forward Guidance and Strategic Roadmap

Looking ahead, the company expects 2026 revenue to grow modestly off the $1.0 billion base as PayGo and direct international strategies temporarily suppress reported sales. Management is aiming for rising margins, neutral free cash flow for the year and pharmacy’s share of sales to move higher, while multiple product milestones and a larger renewal cycle support shipment growth.

Tandem Diabetes Care’s call painted a picture of a business at an inflection point, balancing record results with a willingness to absorb near-term revenue and margin swings to reshape its model. For investors, the key story is less about 2026 top-line optics and more about sustained shipment growth, expanding margins and a pipeline that could underpin a stronger, more recurring earnings profile beyond the transition period.